Trial Profile
Randomised controlled trial of the clinical effectiveness, SafetY and Cost effectiveness of Adalimumab in combination with MethOtRExate for the treatment of juvenile idiopathic arthritis associated uveitis
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 06 Apr 2020
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Juvenile rheumatoid arthritis; Uveitis
- Focus Therapeutic Use
- Acronyms SYCAMORE
- 07 Jun 2019 Status changed from discontinued to completed.
- 21 Jul 2017 According to an AbbVie media release, the Independent Data Safety and Monitoring Committee (IDSMC) recommended unmasking the trial early after 90 randomized patients with active JIA-associated uveitis showed that HUMIRA combined with methotrexate controlled ocular inflammation better and was associated with a significantly lower rate of treatment failure than placebo.
- 21 Jul 2017 According to an AbbVie media release, The review of the marketing authorization application (MAA) is being conducted under the centralized licensing procedure. A marketing authorization decision is anticipated by September. If approved, the authorization will be valid in all 28 member states of the European Union, as well as Iceland, Liechtenstein and Norway.